Gabapentinoid Use among Medicare Beneficiaries during the Post-Stroke Recovery Period
Brooks, J. D.; Bustamante Rocha, R.; Donahue, M. A.; Newhouse, J. P.; Haneuse, S.; Tsai, A.; Moura, L. M. V. R.
Show abstract
BackgroundMost studies of gabapentinoid prescribing trends have focused on younger, commercially insured populations. Patterns among vulnerable groups, including older stroke survivors, remain poorly characterized. We described patterns of gabapentinoid initiation among Medicare beneficiaries following acute ischemic stroke (AIS). MethodsWe analyzed claims data from a 20% sample of U.S. Medicare beneficiaries aged [≥] 65 years hospitalized for AIS between 2009 and 2022. We included individuals enrolled in traditional Medicare for [≥] 12 months before hospitalization, without prior stroke during this interval, and discharged home or to an inpatient destination for [≤]30 days. After excluding those with gabapentinoid use before stroke, we analyzed outpatient gabapentin prescriptions six months after stroke discharge by demographic and clinical characteristics. We calculated the percentage of gabapentinoid initiators by year and U.S. census division, standardized by age, discharge destination, and modified Rankin Score (mRS). ResultsAmong 153,728 Medicare stroke survivors who had not previously been prescribed a gabapentinoid in the 6 months before hospitalization, 4.9% received new prescriptions within 6 months after discharge. The median age was 78 years (Quartile Range: 72 - 84), 55% were female, and 81% were Non-Hispanic White. The crude percentage of gabapentinoid initiators increased from 3.6% in 2009 to 5.8% in 2022. The standardized percentages were 3.8% in 2009 and 5.9% in 2022. We reported a 2.1 percentage point difference in gabapentinoid initiation between U.S. census divisions, with the lowest percentage in the New England Division (3.9%) and the highest in the West South Central Division (6.0%). After standardization, the percentage point difference was 1.9% between the highest and lowest U.S. division. ConclusionThe percentage of U.S. Medicare stroke survivors initiating gabapentinoid increased from 2009 to 2022. We also identified geographic variation, with the highest initiation percentage in the West South Central and the lowest in the New England U.S. Division. Twitter: @MGHValue
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Preliminary outcomes of combined treadmill and overground high-intensity interval training in ambulatory chronic stroke 93%
- Factors Associated with Stroke after COVID-19 Vaccination: A Statewide Analysis 92%
- Short-term Functional Outcomes of Patients with acute intracerebral hemorrhage in the Native and Expatriate Population 90%
Similar papers in this journal
Similar papers in this journal
- Modified Rankin Scale Disability Status at Day 4 Poststroke is an Informative Predictor of Long-Term Day 90 Outcome 94%
- Usage of Mineralocorticoids and Isotonic Crystalloids in Subarachnoid Hemorrhage Patients in the United States 93%
- Documented Goals of Care Conversations with Hospitalized Patients after Severe Stroke 92%
Similar papers in this journal
- Adaptive trials in stroke: Current use & future directions 90%
- Frequency of neurological manifestations in COVID-19: a systematic review and meta-analysis of 350 studies 90%
- Circulating interleukin-6 levels and incident ischemic stroke: a systematic review and meta-analysis of population-based cohort studies 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.